Darwin Global Management’s Cidara Therapeutics CDTX Stock Holding History

Darwin Global Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-997,196	Closed	-$220M	–	8
2025 Q4	$220M	Hold	997,196	–	–	4.46%	4
2025 Q3	$95M	Buy	997,196 +228,772	+30%	+$14.6M	2.64%	4
2025 Q2	$38M	Buy	+768,424	New	+$18.5M	1.59%	3

Darwin Global Management's CDTX Position: Q1 2026 in Review

Darwin Global Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 997,196 shares — an estimated $220M sold.

Darwin Global Management first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $220M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Darwin Global Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Darwin Global Management sold 997,196 Cidara Therapeutics shares in Q1 2026, an estimated $220M.
Darwin Global Management first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Darwin Global Management's Cidara Therapeutics position peaked at $220M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Darwin Global Management's 13F filing for Q1 2026, filed 15 May 2026.